The Alzheimer’s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement

INTRODUCTION: The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer’s disease (AD) clinical trials. ADNI-3, beginning August 1, 2016, is a five year renewal of the current ADNI-2 study. METHODS: ADNI-3 will follow current and additional su...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Alzheimers Dement
Autores principales: Weiner, Michael W., Veitch, Dallas P., Aisen, Paul S., Beckett, Laurel A., Cairns, Nigel J., Green, Robert C., Harvey, Danielle, Jack, Clifford R., Jagust, William, Morris, John C., Petersen, Ronald C., Salazar, Jennifer, Saykin, Andrew J., Shaw, Leslie M, Toga, Arthur W., Trojanowski, John Q.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5536850/
https://ncbi.nlm.nih.gov/pubmed/27931796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2016.10.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares